Efficacy Study of Revlimid® and Low Dose Continuously Administered Melphalan to Treat High Risk MDS

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

January 31, 2012

Study Completion Date

December 31, 2012

Conditions

Myelodysplastic SyndromesLeukemia, Myelomonocytic, ChronicAngiogenesis

Interventions

DRUG

Lenalidomide and melphalan

Lenalidomide (Revlimid) 10 mg po daily for 21d/28 Melphalan (Melphalan) 2 mg po daily for 21d/28

Trial Locations (1)

Sunnybrook Health Sciences Centre, Odette Cancer Center, Toronto